Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Date:8/5/2009

NEW YORK, Aug. 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer (the "Company"), today announced its results for the second quarter ended June 30, 2009.

At June 30, 2009, the Company had cash, cash equivalents, short-term investment securities and interest receivable of $13.4 million, as compared to $15.5 million at December 31, 2008. In addition, at June 30, 2009, the Company had $7.1 million of auction rate securities which are classified as long-term investments. Additionally, in July 2009, the Company received $2.75 million of cash from a settlement with the former licensor of Sulonex (sulodexide). The Company will receive an additional $750,000 on or before July 30, 2010 related to this settlement.

The net income for the second quarter ended June 30, 2009 was $14.1 million, or $0.29 per diluted share, compared to a net loss of $7.7 million, or $0.17 per share, for the second quarter in 2008. The change in net income (loss) was primarily attributable to the recognition of $18.0 million in license revenue relating to an amendment to the September 2007 sublicense agreement with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. (JT/Torii), which eliminated the Company's significant ongoing obligations included in the original agreement, a $1.8 million decrease in research and development expenses related to KRX-0401, and a $1.0 million decrease in research and development expenses related to the cessation of the development of Sulonex in March 2008.

The net income for the six months ended June 30, 2009 was $14.6 million, or $0.30 per diluted
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... Calif. , May 27, 2015  Two years ... biotech professionals, hackers and citizen scientists, Oakland ... $30,000 crowdfunding campaign promoting its mission to democratize science ... Temescal District. ... Based out of ...
(Date:5/27/2015)... Mass. , May 27, 2015  RXi ... company focused on discovering and developing innovative therapies ... today provided an update on the status of the ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... were 3,085 and 21 shares of Series A ...
(Date:5/26/2015)... BELLINGHAM, Washington, USA (PRWEB) May 26, 2015 ... a formal partnership with the Max Planck Society ... Extreme and Quantum Photonics. The center will link two ... of photonics, and will be only the third Max ... SPIE, the international society for optics and photonics, ...
(Date:5/26/2015)... 26, 2015 Innovacyn, a leader ... the human and animal health industries, announced today ... Innovators of Agriculture College Scholarship Award. The scholarship ... exhibits a passionate commitment to the agriculture industry ... year’s winners, Alexis Pedrow from Anderson County Jr/Sr ...
Breaking Biology Technology:East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 2East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3Third Max Planck Centre in North America Inaugurated at University of Ottawa 2Third Max Planck Centre in North America Inaugurated at University of Ottawa 3Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 2Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 3
... 2011 One of the hot topics among healthcare ... requirements in the coming years. Community oncologists, practice administrators ... Use requirements and how these could affect community oncology ... 1 p.m. EDT (10 a.m. PDT) on Thursday, July ...
... we know them, from televisions to computers, depend on conducting ... to pocket sized communications devices and microchips that can fit ... in big demand. Now, Prof. Eran Rabani of Tel ... Sackler Faculty of Exact Sciences, in collaboration with Profs. Uri ...
... Biotechnology, Inc., (OTC: CSBR): Highlights: ... of 41% to $6.9 million Net loss of $3.8 ... Net loss of ($0.10) per share; net loss excluding ... million at year end Annual 2011 Financial ...
Cached Biology Technology:Medicare HIT Incentive Update for the Oncology Practice - Free Educational Webinar 2Medicare HIT Incentive Update for the Oncology Practice - Free Educational Webinar 3Conducting energy on a nano scale 2Conducting energy on a nano scale 3Champions Oncology Reports Full Year 2011 Financial Results 2Champions Oncology Reports Full Year 2011 Financial Results 3Champions Oncology Reports Full Year 2011 Financial Results 4Champions Oncology Reports Full Year 2011 Financial Results 5Champions Oncology Reports Full Year 2011 Financial Results 6
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/7/2015)... , May 7, 2015 ... sensors, FPC1022 and FPC1035, FPC,s smallest touch fingerprint ... are mainly considered for integration on the backside ... smartphone OEMs increased possibilities to integrate touch fingerprint ... size also improves possibilities for module manufacturers to ...
(Date:4/27/2015)...  For more than four decades, AUVSI,s Unmanned ... premier worldwide event for the unmanned land, sea, and ... for any local, national, or trade news organization interested ... and current applications of unmanned technologies. The conference will ... billion industry, and how it will soon impact the ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... be effective in treating kidney disease, report scientists at the ... the online edition of the Proceedings of the National Academies ... drug is rapamycin, also called sirolimus, and is currently used ... new, transplanted kidney. , Over 600,000 people in the ...
... lure of chocolate or the bitter taste of strychnine would ... as to be hard-wired into the brain. Indeed, in studies ... colleagues reported in the January 19, 2006, issue of Neuron ... they said, favor a model for taste encoding in the ...
... is developing a novel gene therapy aimed at selectively ... development of Parkinson's disease. , The gene therapy, described ... Neurology, was designed by Martha Bohn and her laboratory ... , Bohn is Medical Research Council Professor and director ...
Cached Biology News:Scientists discover that widely available drug also helps fight kidney disease 2Scientists discover that widely available drug also helps fight kidney disease 3How taste response is hard-wired into the brain 2Gene therapy 'turns off' mutation linked to Parkinson's disease 2
... Polymerase is a thermostable recombinant DNA polymerase, ... extension and other molecular biology applications. Red ... easy and quick identification of reactions to ... of complete mixing. The inert dye has ...
... immuncapture enzyme-activity assay based on measurenment of ... monoclonal antibody coated microtiter plate. The procedure ... samples or controls, 2nd enzyme reaction) ... is intended for the determination of human ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
Biology Products: